Chemotherapy should be used for patients who have been receiving endocrine therapy and have converted to hormone-refractory prostate cancer. Docetaxel is the standard of care for hormone-refractory prostate cancer, and this regimen prolongs patients’ progression-free survival, overall survival, and provides pain relief and improved quality of life. Of course, there are side effects to this chemotherapy, such as the most dangerous anaphylaxis that can lead to death, and other adverse effects including bone marrow suppression, malaise, edema, neurotoxic effects, and more. Therefore, patients receiving prostate chemotherapy need to sign an informed consent form and are required to be in good general health and able to tolerate a full cycle (approximately 10 sessions every 3 weeks) of chemotherapy.